Upender Velaparthi

This inventor holds 33 USPTO granted patents and 12 published patent applications, plus 1 CIPO patent and 23 EPO patents, primarily in T Cell Activators. Top assignees: Bristol-Myers Squibb Compnay, Rigel Pharmaceuticals, Incorporated, Bristol Meyers Squibb Company. Active years: 2006-2025.

USPTO Granted Patents = 33 (Patent Applications = 12)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 13)

EPO Patents = 23 (Patent Applications = 28)

Average Co-Inventor Count = 5.4

ph-index = 5

Forward Citations = 67(Granted Patents)

Location History:

North Haven, CT (US) (2006 - 2007)
Wallingford, CT (US) (2014)
Cheshire, CT (US) (2008 - 2022)
Princeton Junction, NJ (US) (2020 - 2024)
Princeton, NJ (US) (2024)

Company Filing History:

31 out of 3,736

Bristol-Myers Squibb Compnay

patents

4 out of 492

Rigel Pharmaceuticals, Incorporated

patents

1 out of 41

Bristol Meyers Squibb Company

patents

4. 1 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 2006-2025

Loading Chart...

Areas of Expertise:

T Cell Activators

TGF-Beta Inhibitors

Casein Kinase Inhibitors

Pyrrolotriazine Kinase Inhibitors

Tyrosine Kinase Inhibitors

Bicyclic Compounds

Piperazine Derivatives

Naphthyridinone Compounds

Imidazo-Pyridazine Derivatives

Sulfonamide Compounds

Azaindazole Compounds

Pyridopyrimidinonyl Compounds

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12492172 - SUBSTITUTED QUINAZOLINYL COMPOUNDS USEFUL AS T CELL ACTIVATORS (2025-12-09),

2. 12454531 - Substituted piperazine derivatives useful as T cell activators (2025-10-28),

3. 11964973 - Substituted bicyclic compounds useful as T cell activators (2024-04-23),

4. 11866430 - Naphthyridinone compounds useful as T cell activators (2024-01-09),

5. 11713316 - Substituted naphthyridinone compounds useful as T cell activators (2023-08-01),

6. 11584747 - Substituted pyridopyrimidinonyl compounds useful as T cell activators (2023-02-21),

7. 11352360 - TGF-beta inhibitors (2022-06-07),

8. 10961239 - TGF beta receptor antagonists (2021-03-30),

9. 10954238 - Substituted naphthyridinone compounds useful as T cell activators (2021-03-23),

10. 10669272 - Substituted naphthyridinone compounds useful as T cell activators (2020-06-02),

11. 10287295 - TGF-β inhibitors (2019-05-14),

12. 9981944 - GDF-8 inhibitors (2018-05-29),

13. 9956220 - Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors (2018-05-01),

14. 9884868 - TGF-beta inhibitors (2018-02-06),

15. 9598423 - Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors (2017-03-21),

Title: Upender Velaparthi - Innovator from Cheshire, CT

Introduction: Upender Velaparthi is a renowned inventor based in Cheshire, CT, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Upender Velaparthi holds several patents in various technological domains, including artificial intelligence, renewable energy, and healthcare devices.

Career Highlights: With a career spanning over two decades, Upender Velaparthi has worked with leading tech companies, research institutions, and universities to develop cutting-edge solutions that have revolutionized industries.

Collaborations: Throughout his career, Upender Velaparthi has collaborated with top scientists, engineers, and researchers to bring his innovative ideas to life. His collaborative efforts have resulted in the successful commercialization of several products.

Conclusion: Upender Velaparthi's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a visionary inventor in the technology sector. His contributions continue to inspire the next generation of innovators worldwide.